Ascendis Pharma AS
Ownership
Ownership Structure
Who owns Ascendis Pharma AS (ASND)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.8% of the shares are freely tradable; institutional investors hold 103.9%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RA Capital Management, LLC | 16.75 | 10,281,496 | +0.0 | 03/31/2026 |
| venBio Select Advisor LLC | 8.25 | 5,062,500 | -1.0 | 03/31/2026 |
| FMR Inc | 6.32 | 3,876,601 | -6.7 | 03/31/2026 |
| Franklin Templeton Inc | 3.34 | 2,051,948 | +7.4 | 03/31/2026 |
| Massachusetts Financial Services Company | 3.03 | 1,860,669 | -1.4 | 03/31/2026 |
| BlackRock Inc | 1.08 | 661,054 | +5.2 | 03/31/2026 |
| Polar Capital Holdings PLC | 1.06 | 651,712 | +75.9 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 0.99 | 606,348 | -1.9 | 03/31/2026 |
| The Goldman Sachs Group Inc | 0.92 | 566,192 | -5.1 | 03/31/2026 |
| Delaware Management Holdings Inc | 0.91 | 556,427 | +12.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Holtug Lars | Director | 4,000 | 920,400 $ | Sep 2, 2026 | direct |
| Bienaime Jean Jacques | Director | 2,900 | 667,290 $ | Aug 14, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Bodenhoff Mads | SVP & PAO | Sell | 3,000 | 270.19 | 810,570 |
| Sep 8, 2026 | Bodenhoff Mads | SVP & PAO | Other | 3,000 | 110.00 | 330,000 |
| Sep 2, 2026 | Holtug Lars | Director | Sell | 236 | 264.13 | 62,335 |
| Aug 14, 2026 | Bienaime Jean Jacques | Director | Buy | 900 | 246.91 | 222,219 |
| Aug 14, 2026 | Bienaime Jean Jacques | Director | Buy | 1,100 | 245.85 | 270,435 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.